论文部分内容阅读
目的:研究新脂康对高脂血症大鼠的影响,为临床应用提供实验依据。方法:测定高脂饲料致高脂血症大鼠的血清TG、TC、LDL-C、HDL-C、HL及LPL,并以此计算动脉粥样硬化指数AI和冠心指数R-CHR。结果:新脂康能明显降低高脂血症大鼠血清胆固醇、甘油三酯及低密度脂蛋白的含量,明显增加肝脂酶和脂蛋白脂酶的活性,不同程度降低动脉粥样硬化指数AI和冠心指数R-CHR。结论:新脂康预防给药能明显降低高脂血症大鼠的血脂水平,可能对高脂血症和动脉粥样硬化症有防治作用。
Objective: To study the effect of Xinzhikang on hyperlipidemia rats and provide experimental basis for clinical application. Methods: Serum TG, TC, LDL-C, HDL-C, HL, and LPL were determined in hyperlipidemia-induced rats with hyperlipidemia, and atherosclerosis index AI and coronary heart index R-CHR were calculated. Results: Xinzhikang can significantly reduce the serum cholesterol, triglyceride and low-density lipoprotein levels in hyperlipidemia rats, significantly increase the activity of hepatic lipase and lipoprotein lipase, and reduce the atherosclerosis index AI in different degrees. And coronary heart index R-CHR. Conclusion: Xinzhikang can significantly reduce the blood lipid level in hyperlipidemic rats, which may have preventive and therapeutic effects on hyperlipidemia and atherosclerosis.